Daniel Mrak

New insights into T cell - fibroblast interactions and development of synovial pathotypes in #RA patients. Thanks to all coauthors! ard.bmj.com/content/early/…

Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment appr… pubmed.ncbi.nlm.nih.gov/37033944/

In this large-scale cohort (1222 👥) of symptomatic #PAD, no association of ⬆️Lp(a) with 🫀mortality was found over a median observation period of 5 y Read the study by @daniel_mrak &al👇 #secsectitle0035" target="_blank" rel="nofollow noopener">atherosclerosis-journal.com/article/S0021-… #Lpa #Atherosclerosis #CardioTwitter @EASCongress @society_eas

Advantage of mRNA #COVID booster vaccination as compared to vector in non-seroconverted #immunosuppressed patients: new guidance available! Big thanks to all contributors. nature.com/articles/s4146…

Rituximab and 4th COVID-19 vaccination: Continuation of rituximab impaires "boostability". Thanks to our fantastic coautors! #COVID19 #Booster #rituximab ard.bmj.com/content/early/…

Finally out: our randomized controlled trial provides evidence for efficacy of Tocilizumab in PMR pubmed.ncbi.nlm.nih.gov/35210264/

Check out the latest findings on #COVID19 vaccination & rituximab: ▶️vaccinacion induce antibodies in RTX-treated patients once peripheral B cells at least partially repopulate ▶️specific T cells were detected, independent of humoral immune response ard.bmj.com/content/early/…

Finally out: new evidence for efficacy and safety of a #COVID19 booster vaccination in #Rituximab-treated patients. Thanks to all the authors! @MedUni_Wien @kim3_med @DanielAletaha @leoheinz @AberleJudith ard.bmj.com/content/early/…